Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Study Identifier:

15-AVP-786-303

ClinicalTrials.gov Identifier:

NCT02446132

EudraCT Identifier:

2017-002455-29

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Terminated/Withdrawn

Subscribe to Updates

Study Details

Medical Condition

Dementia/Alzheimer

Study Drug

Drug: AVP-786

Date

Dec 2015 - Sep 2024

Phase 1/2

Phase 2/3

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 50 - 90 Years

Requirements Information

Protocol Summary

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.

Study Locations

Location

Status

Location

MD First Research, LLC Site #767

Chandler, Arizona, United States, 85286

Status

N/A

Location

NoesisPharma, LLC

Phoenix, Arizona, United States, 85032

Status

N/A

Location

Perseverance Research Center, LLC

Scottsdale, Arizona, United States, 85254

Status

N/A

Location

Health Initiatives Research

Fayetteville, Arkansas, United States, 72703

Status

N/A

Location

Advanced Research Center, Inc. Site #835

Anaheim, California, United States, 92805

Status

N/A

Location

ATP Clinical Research, Inc. Site #763

Costa Mesa, California, United States, 92626

Status

N/A